Peptron Shares Rebound to 92,400 Won... On GLP-1 Patent Efficacy Duration Interpretation, Company Says 'Two Weeks Is Not the Maximum'
Peptron rose during trading on the 16th, recovering the 90,000-won level. As the company clarified the facts regarding the interpretation of the efficacy duration surrounding its long-acting GLP-1 formulation patent, the stock price is also showing a rebounding trend. Trading at 92,400 won, up 4,10

Peptron rose during trading on the 16th, recovering the 90,000-won level. As the company clarified the facts regarding the interpretation of the efficacy duration surrounding its long-acting GLP-1 formulation patent, the stock price is also showing a rebounding trend.
Trading at 92,400 won, up 4,100 won from the previous close
As of that morning, Peptron was trading at 92,400 won, up 4,100 won (about 4.64%) from the previous day. Compared to the previous close of 88,300 won, the stock climbed back above the 90,000-won mark.
Company position: "A two-week dosing interval does not mean that is the maximum duration"
Peptron recently issued an official statement on the interpretations raised regarding its long-acting GLP-1 formulation patent. The key point is that the two-week dosing interval confirmed in animal experiments should not be taken as the maximum duration of the drug's efficacy.
According to the company, the anti-obesity efficacy test described in the patent specification was a test in which the long-acting formulation was administered to mice made obese through a high-fat diet at intervals of up to two weeks to confirm efficacy. The company explained that this means anti-obesity effects were confirmed when administered at two-week intervals, not that the drug's efficacy disappears after two weeks.
Differences in pharmacokinetics between animals and humans... Mouse half-life of 8 hours vs. 148 hours in humans
The company particularly emphasized that differences in pharmacokinetics between animals and humans must be considered. Peptron explained, citing the European Medicines Agency's (EMA) assessment of semaglutide, that half-lives of approximately 8 hours in mice and approximately 148 hours in humans have been reported. The point is that even for the same compound, the rate at which the drug is eliminated from the body can vary depending on the species. Therefore, it argued, applying the dosing interval used in mice directly to humans to judge the duration of efficacy is inappropriate.
Blood concentration observed for 35 days in rats and 70 days in minipigs... "1–3 month dosing is not based on a single test"
The company also cited other non-clinical test results included in the patent specification. According to Peptron, changes in blood drug concentration were observed for up to 35 days after administration in S.D. rats and up to 70 days in minipigs. It explained that in the minipig test, semaglutide release was also confirmed to last longer than in rats.
The company further stated that the 1–3 month dosing feasibility described in the patent specification is not based on a single mouse test, but was determined by comprehensively considering the formulation's design structure, drug release characteristics, and non-clinical pharmacokinetic test results. It said the patent specification includes content stating that depending on the subject, a single administration can sustain efficacy for more than one month, and that dosing is possible at intervals of one to a maximum of three months.
Caveat: Observing blood concentration is not the same as proving clinical efficacy
However, there is a distinction to be made. The duration of blood concentration maintenance observed in non-clinical tests is not identical to the actual duration of efficacy confirmed in humans. The mere fact that drug concentration was observed for 35 or 70 days does not mean sufficient therapeutic effect can be assumed to have been maintained throughout that period.
Furthermore, the dosing feasibility described in the patent specification does not mean that efficacy and safety have been proven in clinical trials involving humans. The actual dosing interval and therapeutic effect must be confirmed through future clinical validation.
This patent concerns long-acting formulation technology utilizing a specific polymer combination, and the technical characteristic of controlling the drug release period is a key element. Long-acting GLP-1 therapeutics are drawing attention in development trends due to their potential to reduce the number of administrations.
Difficult to attribute the stock rebound solely to one factor... Future clinical validation is key
Meanwhile, it is difficult to conclude that Peptron's stock rebound that day was caused solely by the patent-related disclosure. Going forward, the practical applicability of the patented technology and the results of additional non-clinical and clinical validation are expected to be major focal points for the stock's trajectory.
[This article does not recommend buying or selling any specific stock. The technical descriptions in the patent specification and non-clinical test results must be distinguished from proof of efficacy and safety in humans. Intraday stock prices may fluctuate in real time, and investment decisions and responsibility rest with the investor. AI assistance was used in the writing of this article.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.
![[Breaking] US October Retail Sales Rise 6.8% Year-on-Year, 0.2% Month-on-Month... Economic Indicators in Focus After CPI and PPI](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F627311%2Fa2376e0512277714%2Fvariants%2Fhero.webp&w=1920&q=75)
![[Breaking] Cyberattack via Optimizely Exposes 178 Global Organizations... CNN, BBC, HSBC, and Ledger Also Affected](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F627874%2Ffc472b72a2596aa1%2Fvariants%2Fhero.webp&w=1920&q=75)

